PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. |
| [08-October-2026] |
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction.
Are You a PCRX Shareholder? You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995. There is no cost or obligation to you. What Is Ademi LLP Investigating? Substantial change-of-control benefits available to Pacira insiders in connection with the transaction; Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and The conduct of Pacira's Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders. What Should PCRX Shareholders Do? Guri AdemiAdemi LLP About Ademi LLP Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE Ademi LLP | ||
Company Codes: NASDAQ:PCRX |
View original content to download multimedia:
